Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Sorrento Therapeutics, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sorrento Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Sorrento Therapeutics, Inc. - The report provides overview of Sorrento Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Sorrento Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Sorrento Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Sorrento Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sorrento Therapeutics, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sorrento Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Sorrento Therapeutics, Inc. Snapshot 7 Sorrento Therapeutics, Inc. Overview 7 Key Information 7 Key Facts 7 Sorrento Therapeutics, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Sorrento Therapeutics, Inc. - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Sorrento Therapeutics, Inc. - Pipeline Products Glance 16 Sorrento Therapeutics, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Sorrento Therapeutics, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 20 Sorrento Therapeutics, Inc. - Drug Profiles 21 Cellular Immunotherapy to Target CEA for Oncology 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Cellular Immunotherapy to Target PD-L1 for Oncology 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cellular Immunotherapy to Target PSMA for Prostate Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 BA-0702 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CBA-0710 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Cellular Immunotherapy to Target c-KIT for Solid Tumors 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Cellular Immunotherapy to Target CD123 for Acute Myeloid Leukemia 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Cellular Immunotherapy to Target CD33 for Acute Myeloid Leukemia 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Cellular Immunotherapy to Target GD3 for Solid Tumors 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Cellular Immunotherapy to Target HER-2 for Glioblastoma 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Cellular Immunotherapy to Target HER2 for Oncology 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Cellular Immunotherapy to Target IL13R Alpha2 for Glioblastoma Multiforme 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Cellular Immunotherapy to Target MUC-16 for Ovarian Cancer 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Cellular Immunotherapy to Target ROR1 for Solid Tumor 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibody to Inhibit CD47 for Oncology 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibody to Inhibit Ghrelin for Obesity 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 rituximab biosimilar 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 STI-600 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 STIA-0168 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 STIA-1011 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 STIA-1012 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 STIA-1014 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 STIA-1015 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 STIA-1110 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 STIB-0201 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 STIC-0205 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 STID-0602 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 BC-001 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 clostridium difficile vaccine 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Monoclonal Antibodies for Clostridium difficile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Monoclonal Antibodies for Hepatitis C 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 STI-001 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Sorrento Therapeutics, Inc. - Pipeline Analysis 57 Sorrento Therapeutics, Inc. - Pipeline Products by Target 57 Sorrento Therapeutics, Inc. - Pipeline Products by Route of Administration 59 Sorrento Therapeutics, Inc. - Pipeline Products by Molecule Type 60 Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action 61 Sorrento Therapeutics, Inc. - Recent Pipeline Updates 63 Sorrento Therapeutics, Inc. - Dormant Projects 64 Sorrento Therapeutics, Inc. - Discontinued Pipeline Products 66 Discontinued Pipeline Product Profiles 66 paclitaxel 66 Sorrento Therapeutics, Inc. - Locations And Subsidiaries 67 Head Office 67 Other Locations & Subsidiaries 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Sorrento Therapeutics, Inc., Key Information 7 Sorrento Therapeutics, Inc., Key Facts 7 Sorrento Therapeutics, Inc. - Pipeline by Indication, 2016 9 Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016 12 Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 13 Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016 14 Sorrento Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15 Sorrento Therapeutics, Inc. - Phase II, 2016 16 Sorrento Therapeutics, Inc. - Phase I, 2016 17 Sorrento Therapeutics, Inc. - Preclinical, 2016 18 Sorrento Therapeutics, Inc. - Discovery, 2016 20 Sorrento Therapeutics, Inc. - Pipeline by Target, 2016 57 Sorrento Therapeutics, Inc. - Pipeline by Route of Administration, 2016 59 Sorrento Therapeutics, Inc. - Pipeline by Molecule Type, 2016 60 Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 61 Sorrento Therapeutics, Inc. - Recent Pipeline Updates, 2016 63 Sorrento Therapeutics, Inc. - Dormant Developmental Projects,2016 64 Sorrento Therapeutics, Inc. - Discontinued Pipeline Products, 2016 66 Sorrento Therapeutics, Inc., Subsidiaries 67
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.